{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000038","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-05-12T20:06:30+00:00","discovered_at":"2026-05-12T20:08:00.302384+00:00","generated_at":"2026-05-12T21:28:56.264434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028","bullets":["Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.","~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.","Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.","Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.","Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000038","json":"https://secwatch.observer/filing/0001404644-26-000038.json","markdown":"https://secwatch.observer/filing/0001404644-26-000038.md","text":"https://secwatch.observer/filing/0001404644-26-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/0001404644-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/ngne-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:28:56.264434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1bda64cff16a8e2555c35213c3399266c1c425c","claim":"Neurogene Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end.","evidence_excerpt":"Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/0001404644-26-000038-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}